Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
NTLA.US
id: 1494
Intellia Therapeutics (NTLA) Clinical Trial Misrepresentation Case
D. Massachusetts
Court1:25-cv-10353
Case number07/30/2024
Class period Start01/08/2025
Class period End04/14/2025
Lead Plaintiff motion deadline- $NTLA investors filed a lawsuit against Intellia Therapeutics, alleging the company misled shareholders about the progress and viability of its clinical trial for Alpha-1 (AATD)-associated lung disease.
- On January 9, 2025, Intellia announced it was halting all NTLA-3001 research and cutting 27% of its workforce. Following this news, $NTLA dropped 15%.
Case Details:
Between July 30, 2024, and January 8, 2025, Intellia repeatedly assured investors that its NTLA-3001 gene-editing program was progressing as planned. The company highlighted regulatory approvals, upcoming clinical trials, and positive expectations for the therapy, stating it would begin dosing patients in late 2024.
However, Intellia allegedly failed to disclose that demand for viral-based gene editing was declining in favor of more cost-effective, non-viral delivery methods. This shift made NTLA-3001 an increasingly inefficient program for the company to maintain.
On January 9, 2025, Intellia announced a major company restructuring, stating that it would completely halt NTLA-3001 research and lay off 27% of its workforce to refocus resources on other projects. Investors and analysts reacted negatively to this revelation, realizing that Intellia’s previous statements had misrepresented the viability of NTLA-3001. Following, $NTLA dropped 15%.
Based on these events, $NTLA investors filed a lawsuit against Intellia Therapeutics, claiming the company:
- It misled investors about the progress and feasibility of NTLA-3001.
- It failed to disclose shifting industry trends that made the program financially unsustainable.
Investors believe Intellia misled them about NTLA-3001’s progress and viability while failing to disclose industry shifts that made the program unsustainable.
Case Status
Lead Plaintiff Submission
Alleged Offence
Misleading Statements,
Financial Misrepresentation,
Failure to Disclose
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
01/09/2025
Filing date
02/11/2025
Lead Plaintiff Deadline
04/14/2025